We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Up 9.4% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Moderna (MRNA - Free Report) . Shares have added about 9.4% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Moderna due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Moderna Q1 Earnings Beat Estimates, Revenues Miss
Moderna incurred loss of 35 cents per share in the first quarter of 2020, narrower than the Zacks Consensus Estimate of a loss of 37 cents and the year-ago loss of 40 cents.
Revenues in the quarter were $8.4 million, which missed the Zacks Consensus Estimate of $18.17 million. In the year-ago quarter, revenues were $16 million.
Quarter in Details
Collaboration revenues were $4.5 million, down 68.4% year over year. Grant revenues almost doubled year over year to $3.8 million.
General and administrative expenses were down 11.5% to $24.1 million. Research & development expenses decreased 11.7% to $115.1 million due to a decline in clinical study costs and material costs.
The company ended the quarter with $1.7 billion in cash and cash equivalents, compared with $1.26 billion as of Dec 31, 2019. The company has up to $700 million available in grants and awards.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month. The consensus estimate has shifted -8.46% due to these changes.
VGM Scores
Currently, Moderna has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Moderna has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Up 9.4% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Moderna (MRNA - Free Report) . Shares have added about 9.4% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Moderna due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Moderna Q1 Earnings Beat Estimates, Revenues Miss
Moderna incurred loss of 35 cents per share in the first quarter of 2020, narrower than the Zacks Consensus Estimate of a loss of 37 cents and the year-ago loss of 40 cents.
Revenues in the quarter were $8.4 million, which missed the Zacks Consensus Estimate of $18.17 million. In the year-ago quarter, revenues were $16 million.
Quarter in Details
Collaboration revenues were $4.5 million, down 68.4% year over year. Grant revenues almost doubled year over year to $3.8 million.
General and administrative expenses were down 11.5% to $24.1 million. Research & development expenses decreased 11.7% to $115.1 million due to a decline in clinical study costs and material costs.
The company ended the quarter with $1.7 billion in cash and cash equivalents, compared with $1.26 billion as of Dec 31, 2019. The company has up to $700 million available in grants and awards.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month. The consensus estimate has shifted -8.46% due to these changes.
VGM Scores
Currently, Moderna has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Moderna has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.